Anil Singhvi’s Stock Picks: Genus, Apollo, AstraZeneca set to rally post results; dump Titagarh, avoid Inox Wind

Market expert Anil Singhvi has lined up a powerful list of stock recommendations based on Q4 earnings. On Monday May 2, Singhvi highlighted three strong buys, all of which have posted stellar results. He also issued a sell call on this stock and urged caution on this stock despite record profits.

Genus Power

Genus Power posted a blockbuster performance in the March quarter, with consolidated revenue doubling year-on-year. PAT surged five times while EBITDA grew nearly 4x. Margins rose sharply to 21 per cent from 12.2 per cent. Given this strong showing, Singhvi recommends a buy with price targets of Rs 400, Rs 405 and Rs 415, keeping a stop loss at Rs 390.

AstraZeneca India

AstraZeneca has outperformed across all metrics. Q4 consolidated income jumped 25.4 per cent while EBITDA rose 74.9 per cent. Margins expanded to 18 per cent versus 12.9 per cent last year. PAT rose 47.7 per cent. Singhvi recommends a buy with targets of Rs 8075, Rs 8250 and Rs 8400, with a stop loss at Rs 7800.

Apollo Hospitals

Apollo Hospitals reported a stable quarter with revenue up 13.1 per cent at Rs 5592 crore. That’s in line with estimates. The company is also investing Rs 1229 crore in Bengaluru to set up a 500-bed hospital and acquire a 200-bed facility. Singhvi is bullish on the stock’s future and recommends buying Apollo Hospitals futures with a stop loss at Rs 6850 and targets of Rs 7000, Rs 7075 and Rs 7150.

Titagarh 

Titagarh’s Q4 numbers disappointed the Street. Revenue fell 4.5 per cent and PAT was down 18.4 per cent. EBITDA declined 15.3 per cent and margins narrowed to 10.1 per cent. Singhvi sees more downside and has advised selling the futures with targets of Rs 870, Rs 860 and Rs 850, stop loss at Rs 890.

Inox Wind

Inox Wind posted a massive 141.6 per cent jump in revenue and a 301.5 per cent surge in net profit — the highest ever for the company. However, Singhvi warns that such performance may not be sustainable and advises avoiding the stock in case of a gap-up opening. He expects profit booking at higher levels.

Verdict

With the Q4 earnings season in full swing, Anil Singhvi’s picks offer a blend of fundamental strength and technical cues. Genus Power, AstraZeneca and Apollo Hospitals are buys with solid upside potential, while Titagarh should be avoided due to weak numbers. Inox Wind may tempt traders, but Singhvi urges caution.